ELEVATION ONCOLOGY INC (ELEV)
US28623U1016 - Common Stock
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ...
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and...
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with...
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- --...
7 Top Stocks to Buy for Under $10: May 2024
By diversifying your portfolio with top stocks for under $10, you can profit from companies that are just starting their growth stories.
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024
ELEV stock results show that Elevation Oncology missed analyst estimates for earnings per share the first quarter of 2024.
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
7 Top Stocks Under $7
Stocks under $7 have greater potential for substantial gains because they start off with lower valuations. Here are some of the best now.
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
5 Healthcare Stocks to Buy for 2024
Healthcare stocks have been some of the top performers in 2024, and thanks to the potential of AI, these names will just keep heating up.
5 Healthcare Stocks to Buy for 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips What has been the top-performing stock so far of 2024? If you had said serve...
ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023
ELEV stock results show that Elevation Oncology beat analyst estimates for earnings per share the fourth quarter of 2023.
ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Elevation Oncology (NASDAQ:ELEV) just reported results for the fourth quarter o...
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional...
Trim the Fat: 3 Overbought Stocks Poised for a Pullback
While these companies have seen a stratospheric rise in their market value, they’re now candidates for overbought stocks to sell.
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology Appoints Experienced Clinical Development Leaders Julie Cherrington, Ph.D. and Alan Sandler, M.D. to Board of Directors
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
3 Stock Winners That Are Up 400% or More in 2024
Explore stocks winners of 2024, including MicroCloud, Beamr Imaging, and Elevation Oncology, each seeing 400% gains in a GenAI-led rally.
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...